James Dignam to Glioblastoma
This is a "connection" page, showing publications James Dignam has written about Glioblastoma.
Connection Strength
1.281
-
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024 05 03; 26(5):796-810.
Score: 0.707
-
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20; 43(27):3032-3040.
Score: 0.193
-
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):38-44.
Score: 0.111
-
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro Oncol. 2015 Jul; 17(7):999-1006.
Score: 0.093
-
Reply to M.C. Chamberlain. J Clin Oncol. 2014 May 20; 32(15):1634-5.
Score: 0.088
-
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):699-708.
Score: 0.087